Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

P8624

Sigma-Aldrich

Pirarubicin

≥95% (HPLC)

Sinônimo(s):

THP

Faça loginpara ver os preços organizacionais e de contrato


About This Item

Fórmula empírica (Notação de Hill):
C32H37NO12
Número CAS:
Peso molecular:
627.64
Número MDL:
Código UNSPSC:
51281913
ID de substância PubChem:
NACRES:
NA.85

Nível de qualidade

Ensaio

≥95% (HPLC)

Formulário

powder

solubilidade

ethanol: soluble 25 mg/mL

espectro de atividade do antibiótico

neoplastics

Modo de ação

DNA synthesis | interferes
enzyme | inhibits

Condições de expedição

wet ice

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](OC6CCCCO6)[C@H](C)O5)c4c(O)c3C(=O)c12)C(=O)CO

InChI

1S/C32H37NO12/c1-14-31(45-21-8-3-4-9-42-21)17(33)10-22(43-14)44-19-12-32(40,20(35)13-34)11-16-24(19)30(39)26-25(28(16)37)27(36)15-6-5-7-18(41-2)23(15)29(26)38/h5-7,14,17,19,21-22,31,34,37,39-40H,3-4,8-13,33H2,1-2H3/t14-,17-,19-,21?,22-,31+,32-/m0/s1

chave InChI

KMSKQZKKOZQFFG-NCXNULAVSA-N

Aplicação

Pirarubicin is used to study synergistic cytotoxicity and apoptosis of cancer cells[1][2]. It is used to study how to protect multi-drug resistance cells from anthracycline induced cytotoxicity[3].

Ações bioquímicas/fisiológicas

Pirarubicin, an anthracycline antibiotic that is an analog of doxorubicin, is an antineoplastic drug. Pirarubicin is transported into cells via a sodium-dependent nucleoside transporter.1,2 It is used to intercalate DNA and inhibit the activity of topoisomerase II and induce DNA crosslinking.

Embalagem

10mg,25mg

Outras notas

Keep container tightly closed in a dry and well-ventilated place.

Pictogramas

Health hazard

Palavra indicadora

Danger

Frases de perigo

Classificações de perigo

Carc. 1B - Muta. 1B - Repr. 1B

Código de classe de armazenamento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Akihiro Ito et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(11), 1422-1427 (2013-03-06)
We evaluated the efficacy of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma (UUT-UC). From December 2005 to November 2008, 77 patients clinically diagnosed with UUT-UC
X X Wu et al.
Cancer research, 60(11), 2912-2918 (2000-06-13)
Anti-Fas monoclonal antibody (mAb) kills Fas-expressing cells by apoptosis. Several anticancer agents also mediate apoptosis and may share common intracellular pathways leading to apoptosis with Fas. Thus, we reasoned that combination treatment of drug-resistant cells with anti-Fas mAb and drugs
Y Mizutani et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 5(9), 2605-2612 (1999-09-28)
Resistance to conventional anticancer chemotherapeutic agents remains one of the major problems in the treatment of bladder cancer. Hence, new therapeutic modalities are necessary to treat the drug-resistant cancers. Apo-2 ligand (Apo-2L) is member of the tumor necrosis factor ligand
Romana J R Yanez et al.
PloS one, 12(8), e0183177-e0183177 (2017-08-12)
High-risk human papillomaviruses (hr-HPVs) cause cervical cancer, the fourth most common cancer in women worldwide. A HPV-16 candidate therapeutic vaccine, LALF32-51-E7, was developed by fusing a modified E7 protein to a bacterial cell-penetrating peptide (LALF): this elicited both tumour protection
Joaquim Carreras et al.
Histopathology, 70(4), 595-621 (2016-10-25)
We aimed to define the clinicopathological characteristics of 29 primary sinonasal diffuse large B cell lymphoma (DLBCL In the training set, 82% had a non-germinal center B-cell-like (Hans' Classifier) (non-GCB) phenotype and 18% were Epstein-Barr virus-encoded small RNAs (EBER) DLBCL

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica